BACKGROUND: For new insulin analogs with properties that vary from human insulin, defining activity in units of human insulin based on glycemic lowering efficacy may be challenging. Here we present a new method that can be used to quantify a unit dose of an experimental insulin when the traditional euglycemic clamp method is not adequate. METHODS: Joint modeling of insulin dose and the glycemic outcome variable hemoglobin A1c (HbA1c), where both were response variables, was used to evaluate insulin unit potency for basal insulin peglispro (BIL). The data were from the Phase 3 program for BIL, which included greater than 5500 patients with type 1 or type 2 diabetes who were treated for 26 or 52 weeks with BIL or a comparator insulin. Both basal-bolus and basal insulin only studies were included, and some type 2 diabetes patients were insulin-naïve. RESULTS: The analysis showed that 1 unit of BIL, composed of 9 nmol of active ingredient, had similar or slightly greater potency compared to 1 unit insulin glargine or NPH insulin for all populations. CONCLUSIONS: Despite some limitations, the joint modeling of HbA1c and insulin dose provides a reasonable approach to estimate the relative potency of a new basal insulin versus an established basal insulin.
RCT Entities:
BACKGROUND: For new insulin analogs with properties that vary from humaninsulin, defining activity in units of humaninsulin based on glycemic lowering efficacy may be challenging. Here we present a new method that can be used to quantify a unit dose of an experimental insulin when the traditional euglycemic clamp method is not adequate. METHODS: Joint modeling of insulin dose and the glycemic outcome variable hemoglobin A1c (HbA1c), where both were response variables, was used to evaluate insulin unit potency for basal insulin peglispro (BIL). The data were from the Phase 3 program for BIL, which included greater than 5500 patients with type 1 or type 2 diabetes who were treated for 26 or 52 weeks with BIL or a comparator insulin. Both basal-bolus and basal insulin only studies were included, and some type 2 diabetespatients were insulin-naïve. RESULTS: The analysis showed that 1 unit of BIL, composed of 9 nmol of active ingredient, had similar or slightly greater potency compared to 1 unit insulin glargine or NPH insulin for all populations. CONCLUSIONS: Despite some limitations, the joint modeling of HbA1c and insulin dose provides a reasonable approach to estimate the relative potency of a new basal insulin versus an established basal insulin.
Authors: Vikram P Sinha; Siak Leng Choi; Danny Kwang Wei Soon; Kenneth F Mace; Kwee Poo Yeo; Shufen T H Lim; Daniel C Howey Journal: J Clin Pharmacol Date: 2014-02-13 Impact factor: 3.126
Authors: Reinhard G Bretzel; Ulrike Nuber; Wolfgang Landgraf; David R Owens; Clare Bradley; Thomas Linn Journal: Lancet Date: 2008-03-29 Impact factor: 79.321
Authors: Robert R Henry; Sunder Mudaliar; Theodore P Ciaraldi; Debra A Armstrong; Paivi Burke; Jeremy Pettus; Parag Garhyan; Siak Leng Choi; Scott J Jacober; Mary Pat Knadler; Eric Chen Quin Lam; Melvin J Prince; Namrata Bose; Niels Porksen; Vikram P Sinha; Helle Linnebjerg Journal: Diabetes Care Date: 2014-06-19 Impact factor: 19.112
Authors: Julio Rosenstock; Richard M Bergenstal; Thomas C Blevins; Linda A Morrow; Melvin J Prince; Yongming Qu; Vikram P Sinha; Daniel C Howey; Scott J Jacober Journal: Diabetes Care Date: 2012-11-27 Impact factor: 19.112
Authors: R M Bergenstal; H Lunt; E Franek; F Travert; J Mou; Y Qu; C J Antalis; M L Hartman; M Rosilio; S J Jacober; E J Bastyr Journal: Diabetes Obes Metab Date: 2016-08-03 Impact factor: 6.577
Authors: Mary Courtney Moore; Marta S Smith; Vikram P Sinha; John M Beals; M Dodson Michael; Scott J Jacober; Alan D Cherrington Journal: Diabetes Date: 2013-10-02 Impact factor: 9.461